Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42732   clinical trials with a EudraCT protocol, of which   7035   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001643-39
    Sponsor's Protocol Code Number:2215-CL-0302
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-01-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-001643-39
    A.3Full title of the trial
    A Phase 3 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
    Sperimentazione di fase 3 multicentrica, randomizzata, in doppio cieco, controllata con placebo dell’inibitore della FLT3 gilteritinib (ASP2215) somministrato come terapia di mantenimento in seguito a terapia di induzione/consolidamento in soggetti affetti da LMA con mutazione FLT3/ITD alla prima remissione completa
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effectiveness and safety of gilteritinib (ASP2215) as maintenance treatment (maintain the response achieved during the first course of treatment) for Acute myeloid leukemia patients who are in a first complete remission (no residual leukemia cells in your bone marrow), with mutations in the FLT3 gene compared to placebo given alone.

    Efficacia e sicurezza di gilteritinib (ASP2215) come terapia di mantenimento (mantenere la risposta ottenuta durante il primo ciclo di trattamento) per i pazienti con leucemia mieloide acuta in prima remissione completa (non le cellule leucemiche residue nel midollo osseo), con mutazioni nel gene FLT3 rispetto al placebo somministrato da solo.
    A.3.2Name or abbreviated title of the trial where available
    Effectiveness and safety of gilteritinib (ASP2215) as maintenance treatment (maintain the response
    Efficacia e sicurezza di gilteritinib (ASP2215) come terapia di mantenimento (mantenere la risposta
    A.4.1Sponsor's protocol code number2215-CL-0302
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Global Development, Inc. (APGD)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstellas Pharma Europe B.V.
    B.5.2Functional name of contact pointService Desk - Global Clinical Dev.
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 BE
    B.5.3.4CountryNetherlands
    B.5.4Telephone number0031715455878
    B.5.5Fax number0031715455224
    B.5.6E-mailcontact@nl.astellas.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGilterinitib
    D.3.2Product code [ASP2215]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGILTERITINIB
    D.3.9.2Current sponsor codeASP2215
    D.3.9.4EV Substance CodeSUB177203
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects diagnosed with FLT3/ITD acute myeloid leukemia (AML) in CR1, including CRp and CRi, for whom a decision not to proceed with transplantation has been made, or a suitable donor could not be identified.
    Soggetti affetti da leucemia mieloide acuta (LMA) con mutazione FLT3/ITD alla CR1, tra cui CRp e Cri, per i quali è stata presa la decisione di non procedere con il trapianto, o non si è potuto identificare un donatore compatibile.
    E.1.1.1Medical condition in easily understood language
    AML is cancer of myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in bone marrow and interfere with production of normal blood cells.
    LMA è un tumore della linea mieloide delle cellule del sangue caratterizzato dalla rapida crescita anormale dei globuli bianchi che si accumulano nel midollo osseo ed interferiscono con la normale...
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to compare relapse-free survival (RFS) between subjects with FLT3/ITD AML in first complete remission (CR1) without transplant and who are randomized to receive gilteritinib or placebo beginning after completion of induction/consolidation chemotherapy for a 2-year
    period.
    L’obiettivo primario è di confrontare la sopravvivenza libera da recidiva (relapse-free survival, RFS) nei soggetti affetti da leucemia mieloide acuta (LMA) con mutazione tirosin chinasi 3 FMS-simile (FMS-like tyrosine kinase 3, FLT3)/interno duplicazione in tandem (internal tandem duplication, ITD) alla prima remissione completa (first complete remission, CR1) senza trapianto e che sono randomizzati a ricevere gilteritinib o placebo dopo il completamento della chemioterapia di induzione/consolidamento per un periodo di 2 anni.
    E.2.2Secondary objectives of the trial
    Key Secondary Objective:
    ¿Compare overall survival (OS) in subjects treated with gilteritinib as maintenance therapy after induction/consolidation with those treated with placebo.
    Additional Secondary Objectives:
    ¿Event-free survival (EFS), AEs, clinical laboratory, vital signs, electrocardiograms (ECGs) and Eastern Cooperative Oncology Group (ECOG) performance scores.
    ¿ Examine the relationship of minimal residual disease (MRD), as determined using a next-generation sequencing (NGS) platform specific to FLT3/ITD mutations, with RFS and OS.
    L’obiettivo secondario chiave è:
    ¿Confrontare la sopravvivenza complessiva (overall survival, OS) nei soggetti trattati con gilteritinib come terapia di mantenimento dopo la terapia di induzione/consolidamento con quelli trattati con placebo.
    Gli obiettivi secondari sono:
    ¿Sopravvivenza senza eventi (event-free survival, EFS), eventi avversi (AE), clinica di laboratorio, parametri vitali, elettrocardiogrammi (ECG), punteggi della prestazione del Gruppo Cooperativo Orientale dell’Oncologia (Eastern Cooperative Oncology Group, ECOG).
    ¿Esaminare il rapporto tra malattia residua minima (minimal residual disease, MRD), stabilita utilizzando una piattaforma di sequenziamento di nuova generazione (next-generation sequency, NGS) specifica per le mutazioni FLT3/ITD, e RFS e OS.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Pharmacogenomics
    Version: -
    Date: 05/10/2016
    Title: Retrospective Pharmacogenomics Substudy (Optional)
    Objectives: The PGx research that may be conducted in the future with acquired blood samples and/or buccal swab is exploratory. The objective of this
    research will be to analyze or determine genes of relevance to clinical response, pharmacokinetics, and toxicity/safety issues. By analyzing genetic variations, it may be possible to predict an individual subject's response to treatment in terms of efficacy and/or toxicity.

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Pharmacokinetic sampling substudy:
    Sparse (predose) pharmacokinetic samples will be collected in all subjects.
    Additional ECGs and/or time-matched plasma samples will be collected in a subset of approximately 90 subjects (targeting approximately 60 subjects in the gilteritinib arm and 30 subjects in the placebo arm) at the following visits and time points:
    ¿ Day 15 – 4 hours (± 1 hour) postdose
    ¿ Day 29 – 4 hours (± 1 hour) postdose

    Farmacogenomica
    Versione: -
    Data: 05/10/2016
    Titolo: Sottostudio retrospettivo di farmacogenomica (Opzionale)
    Obiettivi: La ricerca PGx che può essere condotta in futuro con campioni di sangue acquisiti o tamponi boccali è di tipo esplorativa. L'obiettivo di questa ricerca sarà di analizzare o determinare i geni di rilevanza alla risposta clinica, farmacocinetica, e problemi di tossicità/sicurezza. Con l'analisi delle variazioni genetiche, sarà possobile predirre la risposta al trattamento per ogni soggetto in termini di efficacia e/o tossicità.

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Sottostudio farmacocinetico di campionamento:
    i campioni di farmacocinetica (predose) saranno raccolti per tutti i soggetti.
    Addizionalmente saranno raccolti ulteriori ECG e/o campioni di plasma tempo-abbinati in un sottogruppo di circa 90 soggetti (individuando circa 60 soggetti nel braccio di gilterinib e 30 soggetti nel braccio del placebo) alle seguenti visite e punti temporali:
    ¿ Giorno 15 - 4 ore (± 1 ora) postdose
    ¿ Giorno 29 - 4 ore (± 1 ora) postdose
    E.3Principal inclusion criteria
    1. Written informed consent must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
    2. Subject is considered an adult according to local regulation at the time of signing informed consent form (ICF).
    3. Subject consents to allow access to his or her diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test for gilteritinib.
    4. Subject has confirmed morphologically documented AML excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as < 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
    5. Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or a suitable donor could not be identified.
    6. Subject is < 2 months from the start of the last cycle of consolidation and should have completed the recommended number of consolidations per local practice.
    7. Subject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.
    8. Subject has had presence of the FLT3/ITD activating mutation in the bone marrow or peripheral blood as determined by the local institution at diagnosis.
    9. Subject has an ECOG performance status 0 to 2.
    10. Subject must meet the following criteria as indicated on the clinical laboratory tests:
    ¿ Serum creatinine = 1.5 x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
    ¿ Serum total bilirubin =2,5 mg/dL (43 µmol/L), except for subjects with Gilbert’s syndrome.
    ¿ Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.
    ¿ Serum potassium and serum magnesium = institutional lower limit of normal (LLN).
    ¿ Absolute neutrophil count (ANC) = 500/µl and platelets = 20000/µl (unsupported by transfusions).
    11. Subject is suitable for oral administration of study drug.

    For Inclusion Criteria 12-17 see Protocol
    1. Il modulo di consenso informato scritto e l’informativa sulla privacy approvati dal comitato etico indipendente secondo le normative nazionali (ad esempio, l’Autorizzazione secondo la legge sulla portabilità e sulla responsabilità delle polizze di assicurazione sanitaria [Health Insurance Portability and Accountability Act, HIPAA] per i centri negli Stati Uniti) devono essere ottenuti dal soggetto o dal rappresentante legale prima di qualsiasi procedura correlata con lo studio (incluso il ritiro di farmaci proibiti, se applicabile).
    2. Il soggetto è considerato un adulto secondo le normative locali al momento della firma del modulo di consenso informato (Informed Consent Form, ICF).
    3. Il soggetto accetta di consentire l’accesso al suo aspirato diagnostico di midollo osseo o al suo campione di sangue periferico e/o al DNA derivato da tale campione, se disponibili, che potrebbero essere utilizzati per convalidare un test diagnostico per gilteritinib.
    4. Un soggetto presenta una LMA confermata, escludendo la leucemia promielocitica acuta (LPA) documentata morfologicamente alla CR1 (compresi CRp e CRi). Ai fini dell’arruolamento, la CR sarà definita come <5% di blasti nel midollo osseo senza caratteristiche morfologiche di leucemia acuta (ad esempio, corpi di Auer) nel midollo osseo, senza evidenza di malattia extramidollare come il coinvolgimento del sistema nervoso centrale o il sarcoma granulocitico.
    5. Il soggetto non procederà con il trapianto se è stato deciso di non procedere in tal senso sia su raccomandazione del medico sia se non è stato individuato alcun donatore idoneo.
    6. Per il soggetto non sono trascorsi più di 2 mesi dall’ultimo ciclo di consolidamento e deve avere completato il numero raccomandato di consolidamenti secondo pratica locale.
    7. Il soggetto non ha fatto alcun uso di agenti sperimentali, ad eccezione degli agenti inibitori di FLT3 durante la terapia di induzione e/o consolidamento, nelle precedenti 4 settimane.
    8. Il soggetto ha manifestato la mutazione attivante FLT3/ITD nel midollo osseo o nel sangue periferico al momento della diagnosi come stabilito dall’istituzione locale.
    9. Il soggetto ha un valore di stato della prestazione ECOG da 0 a 2.
    10. Il soggetto deve soddisfare i seguenti criteri come indicato nei test clinici di laboratorio:
    •Creatinina sierica =1,5 × limite superiore della normalità (upper limit of normal, ULN) istituzionale, o se la creatinina sierica è fuori il range di normalità, quindi il tasso di filtrazione glomerulare (glomerular filtration rate, GFR) >40 ml/min/1,73 m2 come calcolato con l’equazione della modifica della dieta nella malattia renale (Modification of Diet in Renal Disease, MDRD) a 4 parametri.
    •Bilirubina totale sierica =2,5 mg/dl (43 µmol/l), ad eccezione dei soggetti affetti da sindrome di Gilbert.
    •Aspartato aminotransferasi (AST) sierica e alanina aminotransferasi (ALT) <3 x ULN.
    •Potassio sierico e magnesio sierico = limite inferiore della normalità (lower limit of normal, LLN) istituzionale.
    •Conta assoluta dei neutrofili (CAN) =500/µl e piastrine =20000/µl (non supportato da trasfusioni).
    11.Il soggetto è idoneo per la somministrazione orale del farmaco in studio.

    Per i Criteri di inclusione 12-17 vedere il Protocollo
    E.4Principal exclusion criteria
    1.Subject has had prior allogeneic transplant.
    2. Subject has QTcF interval > 450 msec (average of triplicate determinations based on central reading).
    3. Subject with Long QT Syndrome.
    4. Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).
    5. Subject has clinically active central nervous system leukemia.
    6. Subject is known to have human immunodeficiency virus infection.
    7. Subject has active hepatitis B or C.
    8. Subject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.
    9. Subject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
    10. Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is = 45%.
    11. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
    12. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
    13. Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.

    For Exclusion Criteria 14-16 see Protocol
    1.Il soggetto è stato sottoposto precedentemente a un trapianto allogenico.
    2.Il soggetto presenta un intervallo QTcF >450 msec (media triplicata di determinazioni basate suna lettura centrale).
    3.Soggetto affetto dalla sindrome del QT lungo.
    4.Il soggetto presenta ipocalemia e ipomagnesiemia allo screening (definita come valori inferiori al LLN).
    5.Il soggetto è affetto da leucemia del sistema nervoso centrale clinicamente attiva.
    6.Il soggetto è affetto da infezione da virus dell’immunodeficienza umana.
    7.Il soggetto è affetto da epatite B o C attiva.
    8.Il soggetto presenta un’infezione non controllata. Se è presente un’infezione batterica o virale, il soggetto deve ricevere la terapia definitiva e non deve presentare segni di progressione dell’infezione da 72 ore prima della randomizzazione. Se è presente un’infezione fungina, il soggetto deve essere sottoposto a terapia sistemica definitiva anti-fungina e non deve presentare segni di progressione dell’infezione da 1 settimana prima della randomizzazione.
    9.Il soggetto presenta un’infezione in progressione definita come instabilità emodinamica attribuibile a sepsi o nuovi sintomi, parametri vitali in peggioramento o esiti radiografici attribuibili a un’infezione. Una febbre persistente che non presenta altri segni o sintomi non verrà interpretata come un’infezione in progressione.
    10.Il soggetto presenta angina non controllata, aritmie ventricolari gravi non controllate, evidenza elettrocardiografica di ischemia acuta, insufficienza cardiaca congestizia secondo la New York Heart
    Classe 3 o 4 secondo l’associazione (New York Hearth Association, NYHA) o il soggetto presenta nell’anamnesi un’insufficienza cardiaca congestizia di classe 3 o 4 secondo la NYHA in passato, a meno che un ecocardiogramma di screening o una scansione da acquisizione a gate multipli (multigated acquisition, MUGA) eseguita entro 1 mese prima di studiare i risultati di ingresso in una frazione di eiezione ventricolare sinistra che è =45%.
    11.Il soggetto necessita di essere trattato con farmaci concomitanti che sono forti induttori del citocromo P450 (CYP) 3A.
    12.Il soggetto necessita di essere trattato con farmaci concomitanti che sono forti inibitori o induttori della glicoproteina-P (P-gp), ad eccezione dei farmaci che sono considerati assolutamente fondamentali per la cura del soggetto.
    13.Il soggetto necessita di essere trattato con farmaci concomitanti che bersagliano il recettore 1 della serotonina 5-idrossitriptamina (5HT1R) o il recettore 2B della 5-idrossitriptamina (5HT2BR) o il recettore sigma non specifico, ad eccezione dei farmaci che sono considerati assolutamente fondamentali per la cura del soggetto.

    Per i Criteri di Esclusione 14-16 vedere il Protocollo
    E.5 End points
    E.5.1Primary end point(s)
    Relapse-free survival (RFS)
    Leukemia relapse will be defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts,
    any extramedullary blast foci as per Revised International Working Group (IWG) criteria.
    Sopravvivenza libera da recidiva (RFS)
    La recidiva da leucemia sarà definita come blasti nel midollo osseo pari al 5% o superiore (non imputabili alla rigenerazione del midollo osseo), eventuali blasti circolanti, qualunque focolaio di blasti extramidollare secondo i criteri revisionati del Gruppo di Lavoro Internazionale (International Working Group, IWG).
    E.5.1.1Timepoint(s) of evaluation of this end point
    RFS: the time from randomization until relapse or death from any cause, whichever comes first.
    RFS: il tempo dalla randomizzazione fino alla recidiva o morte per qualsiasi causa, ciò che viene prima.
    E.5.2Secondary end point(s)
    Key Secondary Endpoints:
    ¿ Overall survival (OS)
    Additional secondary efficacy endpoints:
    ¿ Event-free survival (EFS)
    ¿ Minimal residual disease (MRD)
    Safety Endpoints
    ¿ AEs
    ¿ Serum chemistry, hematology, coagulation and urinalysis
    ¿ Vital signs
    ¿ ECGs
    ¿ Physical examination findings
    ¿ Eastern Cooperative Oncology Group (ECOG) performance status
    L’endpoint secondario principali è:
    ¿ OS, definita come il tempo dalla randomizzazione fino al decesso per qualsiasi causa.
    Gli endpoint secondari sono:
    ¿ EFS
    ¿ MRD
    ¿ AE
    ¿ Chimica del siero, ematologia, coagulazione e analisi delle urine
    ¿ Parametri vitali
    ¿ ECG
    ¿ Risultati dell’esame obiettivo
    ¿ Stato della prestazione del gruppo oncologico cooperativo esterno (ECOG)
    E.5.2.1Timepoint(s) of evaluation of this end point
    OS: the time from randomization until death from any cause.
    OS: il tempo dalla randomizzazione fino alla morte per qualsiasi causa.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Brazil
    Canada
    Chile
    Croatia
    Czechia
    Denmark
    France
    Germany
    Greece
    Hungary
    Israel
    Italy
    Japan
    Korea, Democratic People's Republic of
    Korea, Republic of
    Poland
    Portugal
    Romania
    Serbia
    Spain
    Sweden
    Taiwan
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial in all participating countries is defined as the last subject’s last contact.
    La fine dello studio in tutti i paesi partecipanti è definito come l'ultimo contatto dell'ultimo soggetto.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 85
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 8
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 54
    F.4.2.2In the whole clinical trial 94
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    NONE
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-12-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-31
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA